Turn Biotechnologies develops mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue.
Employees: 11-50
Founded date: 2018
Investors 3
| Date | Name | Website |
| 18.11.2021 | Khosla Ven... | khoslavent... |
| - | Formic Ven... | formic.vc |
| 12.12.2020 | Shanda Gro... | shanda.com |
Mentions in press and media 10
| Date | Title | Description |
| 28.07.2024 | HanAll Biopharma: Navigating Challenges and Opportunities in Q2 2024 | HanAll Biopharma, a global player in the biopharmaceutical arena, recently unveiled its financial results for the second quarter of 2024. The numbers tell a story of resilience amid challenges. Total revenue reached 31.6 billion KRW, a slig... |
| 26.07.2024 | HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update | HanAll reports strong financial performance with second quarter total revenue of 31.6 billion KRW, driven by the strong sales from the key products. HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agree... |
| 26.07.2024 | HanAll Biopharma Reports Q2 2024 Financial Results and Provides Business Update | HanAll reports strong financial performance with second quarter total revenue of 31.6 billion KRW, driven by the strong sales from the key products. HanAll expands collaboration with Turn Biotechnologies through an exclusive licensing agree... |
| 28.05.2024 | HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases | Exclusive agreement allows HanAll to utilize Epigenetic Reprogramming of Aging (ERATM) technology for ophthalmic and otic diseases. Collaboration aims to leverage HanAll's extensive expertise in ophthalmic and otic diseases and Turn Bio's c... |
| 28.05.2024 | Turn Biotechnologies Signs Global Licensing Agreement with HanAll Biopharma to Develop Eye and Ear Therapies | Synergistic collaboration to revolutionize age-related therapies worldwide Deal valued at over $300 million USD for initial product MOUNTAIN VIEW, Calif., May 28, 2024 /PRNewswire/ -- Turn Biotechnologies, a developer of novel mRNA medicine... |
| 28.05.2024 | HanAll Biopharma Signs Licensing Agreement with Turn Biotechnologies to Develop Novel Treatments for Eye and Ear Diseases | Exclusive agreement allows HanAll to utilize Epigenetic Reprogramming of Aging (ERATM) technology for ophthalmic and otic diseases. Collaboration aims to leverage HanAll's extensive expertise in ophthalmic and otic diseases and Turn Bio's c... |
| 10.03.2023 | Tweekly. Выпуск 160. Бессмертие как сервис | Что сейчас растёт и как это применить 1. Бессмертие как сервис (IaaS). То, чего все хотят и боятся одновременно. 2. Цифровые клоны городов и производств — быстрая проверка «капиталоемких» гипотез. Следующий шаг - проверка жизнеспособности п... |
| 13.04.2022 | HanAll Biopharma and Daewoong Pharmaceutical Invest in Turn Biotechnologies to Expand Growth Initiative | HanAll Biopharma and Daewoong Pharmaceutical invest in the broad potential of Turn Biotechnologies Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases SEOUL, S... |
| 11.04.2022 | Daewoong Pharmaceutical and HanAll Biopharma Invest in Turn Biotechnologies to Expand Growth Initiative | Daewoong Pharmaceutical and HanAll Biopharma invest in the broad potential of Turn Biotechnologies Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases SEOUL, S... |
| 28.04.2021 | Biotech startup Turn Biotechnologies raises new funding to develop novel RNA medicines for untreatable age-related conditions | Turn Biotechnologies is a Silicon Valley-based tech startup and a Stanford University spinout that is developing mRNA medicines that induce the body to heal itself by instructing specific cells to fight disease or repair damaged tissue. Us... |